JP2008531604A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531604A5 JP2008531604A5 JP2007557300A JP2007557300A JP2008531604A5 JP 2008531604 A5 JP2008531604 A5 JP 2008531604A5 JP 2007557300 A JP2007557300 A JP 2007557300A JP 2007557300 A JP2007557300 A JP 2007557300A JP 2008531604 A5 JP2008531604 A5 JP 2008531604A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- glucopyranoso
- pyrano
- thiazoline
- dideoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 15
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 13
- -1 acetoxymethyl Chemical group 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- YQHOHPOCZUAUKP-UHFFFAOYSA-N n-[(aminooxy)carbonyl]aniline Chemical compound NOC(=O)NC1=CC=CC=C1 YQHOHPOCZUAUKP-UHFFFAOYSA-N 0.000 claims 6
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 claims 5
- AREJBZPGVDSCFV-LMHBHQSJSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-(2-methylpropyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CC(C)C)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O AREJBZPGVDSCFV-LMHBHQSJSA-N 0.000 claims 5
- QWLSGKMXAHXJDM-LMHBHQSJSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-butyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CCCC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O QWLSGKMXAHXJDM-LMHBHQSJSA-N 0.000 claims 5
- PFPXOCGKVAYLDW-DIAXPKBXSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-ethyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O PFPXOCGKVAYLDW-DIAXPKBXSA-N 0.000 claims 5
- COARJWAHYFNYJD-JVNHZCFISA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-pentyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CCCCC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O COARJWAHYFNYJD-JVNHZCFISA-N 0.000 claims 5
- QZKZZLAADHHBPD-UTGUJQJDSA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-propan-2-yl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(C(C)C)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O QZKZZLAADHHBPD-UTGUJQJDSA-N 0.000 claims 5
- VRJFQCRQLPVYQE-JPIRQXTESA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-propyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound S1C(CCC)=N[C@H]2[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@@H]2OC(C)=O VRJFQCRQLPVYQE-JPIRQXTESA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 4
- VUWIPARUGVLNEP-NENRSDFPSA-N (3ar,5r,6s,7r,7ar)-2-butyl-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(CCCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O VUWIPARUGVLNEP-NENRSDFPSA-N 0.000 claims 3
- ACNLJPLCGRIHJF-GPMKSPRZSA-N (3ar,5r,6s,7r,7ar)-2-ethyl-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(CC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O ACNLJPLCGRIHJF-GPMKSPRZSA-N 0.000 claims 3
- DRHXTSWSUAJOJZ-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-methyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(C)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O DRHXTSWSUAJOJZ-FMDGEEDCSA-N 0.000 claims 3
- QWOPEBCGKASVQP-QXOHVQIXSA-N (3ar,5r,6s,7r,7ar)-5-(hydroxymethyl)-2-propyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(CCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O QWOPEBCGKASVQP-QXOHVQIXSA-N 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- HFGXRMOCEYNLGH-DHGKCCLASA-N [(3ar,5r,6s,7r,7ar)-6,7-diacetyloxy-2-methyl-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazol-5-yl]methyl acetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]2SC(C)=N[C@@H]21 HFGXRMOCEYNLGH-DHGKCCLASA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 2
- 229940124639 Selective inhibitor Drugs 0.000 claims 2
- UIPOTIGLSUPBEG-VBSBHUPXSA-N [(2R,3S,4R,5R)-3,4-diacetyloxy-6-(phenylcarbamoyloxyimino)-5-(propanoylamino)oxan-2-yl]methyl acetate Chemical compound CCC(=O)N[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)OC1=NOC(=O)NC1=CC=CC=C1 UIPOTIGLSUPBEG-VBSBHUPXSA-N 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 125000006755 (C2-C20) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ITVRELFVFCOUMV-NMFUWQPSSA-N [[(3r,4r,5s,6r)-3-(butanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 ITVRELFVFCOUMV-NMFUWQPSSA-N 0.000 claims 1
- VIUUSOMOWDCFGS-MWQQHZPXSA-N [[(3r,4r,5s,6r)-3-(hexanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 VIUUSOMOWDCFGS-MWQQHZPXSA-N 0.000 claims 1
- QIDNPKQVOUOABR-AAVRWANBSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(2-methylpropanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CC(C)C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 QIDNPKQVOUOABR-AAVRWANBSA-N 0.000 claims 1
- CNCUWUMEUHOGHK-DTZQCDIJSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(3-methylbutanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CC(C)CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 CNCUWUMEUHOGHK-DTZQCDIJSA-N 0.000 claims 1
- NUNQIQQEEPOGDJ-DTZQCDIJSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(pentanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 NUNQIQQEEPOGDJ-DTZQCDIJSA-N 0.000 claims 1
- ADGOMNHDQHIKMZ-FMKGYKFTSA-N [[(3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(propanoylamino)oxan-2-ylidene]amino] n-phenylcarbamate Chemical compound CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1=NOC(=O)NC1=CC=CC=C1 ADGOMNHDQHIKMZ-FMKGYKFTSA-N 0.000 claims 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 244000144992 flock Species 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940005605 valeric acid Drugs 0.000 claims 1
- 0 *C[C@]([C@]1O)O[C@]2NC(*)=*[C@@]2[C@]1O Chemical compound *C[C@]([C@]1O)O[C@]2NC(*)=*[C@@]2[C@]1O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65687805P | 2005-03-01 | 2005-03-01 | |
| US60/656,878 | 2005-03-01 | ||
| PCT/CA2006/000300 WO2006092049A1 (en) | 2005-03-01 | 2006-03-01 | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008531604A JP2008531604A (ja) | 2008-08-14 |
| JP2008531604A5 true JP2008531604A5 (enExample) | 2011-01-27 |
| JP5154954B2 JP5154954B2 (ja) | 2013-02-27 |
Family
ID=36940808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557300A Expired - Fee Related JP5154954B2 (ja) | 2005-03-01 | 2006-03-01 | 選択的なグリコシダーゼインヒビター、インヒビターを作製する方法、およびインヒビターの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080287375A1 (enExample) |
| EP (2) | EP2436687A1 (enExample) |
| JP (1) | JP5154954B2 (enExample) |
| CN (1) | CN101208352B (enExample) |
| AU (1) | AU2006220187B2 (enExample) |
| CA (2) | CA2599843C (enExample) |
| WO (1) | WO2006092049A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1734821A4 (en) * | 2004-04-14 | 2011-07-06 | Uab Research Foundation | ACTIVATORS OF HEXOSAMIN BINOSYNTHESIS AS AN INHIBITORS FOR INDUCED DAMAGE CAUSED BY ISCHEMIC SHOCK OR HEMORRHAGIC SHOCK |
| CN107253970A (zh) * | 2006-08-31 | 2017-10-17 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| EP2057171A4 (en) * | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| GB0622702D0 (en) * | 2006-11-15 | 2006-12-27 | Univ Dundee | Selective glycosidase inhibitors |
| US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
| US9079868B2 (en) * | 2008-08-01 | 2015-07-14 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010012106A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20110301217A1 (en) * | 2008-09-16 | 2011-12-08 | David Jaro Vocadlo | Selective Glycosidase Inhibitors and Uses Thereof |
| US9120781B2 (en) * | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
| WO2012040719A2 (en) * | 2010-09-24 | 2012-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders |
| US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
| US8901087B2 (en) * | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| EP2638052B1 (en) | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
| PL2655388T3 (pl) | 2010-12-23 | 2016-12-30 | Selektywne inhibitory glikozydazy i ich zastosowania | |
| WO2012126091A1 (en) * | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012129802A1 (en) * | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof |
| US9718854B2 (en) | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9409924B2 (en) | 2011-06-27 | 2016-08-09 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726492B1 (en) | 2011-06-27 | 2017-11-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013025452A1 (en) * | 2011-08-18 | 2013-02-21 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| EA022562B1 (ru) * | 2011-08-25 | 2016-01-29 | Мерк Патент Гмбх | ПИРАНО[3,2-d][1,3]ТИАЗОЛ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОЗИДАЗЫ |
| RU2707292C2 (ru) * | 2012-05-08 | 2019-11-26 | Мерк Шарп И Доум Корп. | Проницаемые ингибиторы гликозидазы и их применения |
| WO2014032188A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014032185A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014052453A1 (en) | 2012-09-25 | 2014-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
| RU2672873C2 (ru) | 2012-10-31 | 2018-11-20 | Алектос Терапьютикс Инк. | Ингибиторы гликозидаз и их применения |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| WO2014171206A1 (ja) * | 2013-04-17 | 2014-10-23 | Yuasa Tomoyuki | 糖尿病治療薬の新規なスクリーニング方法 |
| JP6563017B2 (ja) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| CA3012560A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| CA3012624A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| WO2019037860A1 (en) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | LINEAR INHIBITORS OF GLYCOSIDASE |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| KR102839500B1 (ko) | 2018-08-22 | 2025-07-28 | 아셰뉴론 에스아 | 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염 |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| CN114524854B (zh) * | 2022-02-25 | 2023-05-26 | 中国农业大学 | 一种糖基芳香环碳苷衍生物及其制备方法与应用 |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
| CN116376875B (zh) * | 2023-03-03 | 2024-02-23 | 云南师范大学 | 耐热性提高的n-乙酰氨基葡萄糖苷酶突变体及其应用 |
| CN116555229B (zh) * | 2023-05-25 | 2024-09-20 | 云南师范大学 | N-乙酰氨基葡萄糖苷酶突变体、重组表达载体及菌和应用 |
| CN118086249B (zh) * | 2024-01-24 | 2024-12-06 | 云南师范大学 | 一种协同提高酶活和热稳定性的n-乙酰氨基葡萄糖苷酶突变体及其制备与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818732D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| US6774140B1 (en) * | 1999-05-11 | 2004-08-10 | The Scripps Research Institute | Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| WO2002072860A1 (en) * | 2001-03-14 | 2002-09-19 | Denki Kagaku Kogyo Kabushiki Kaisha | Process for producing hyaluronic acid or its derivative |
| US20070066543A1 (en) * | 2003-05-22 | 2007-03-22 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| EP2057171A4 (en) * | 2006-08-31 | 2010-04-21 | Univ Fraser Simon | SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF |
| US9079868B2 (en) * | 2008-08-01 | 2015-07-14 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010012106A1 (en) * | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US20110301217A1 (en) * | 2008-09-16 | 2011-12-08 | David Jaro Vocadlo | Selective Glycosidase Inhibitors and Uses Thereof |
| US9120781B2 (en) * | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2638052B1 (en) * | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| PL2655388T3 (pl) * | 2010-12-23 | 2016-12-30 | Selektywne inhibitory glikozydazy i ich zastosowania | |
| WO2012126091A1 (en) * | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9718854B2 (en) * | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
-
2006
- 2006-03-01 AU AU2006220187A patent/AU2006220187B2/en not_active Ceased
- 2006-03-01 CA CA2599843A patent/CA2599843C/en not_active Expired - Fee Related
- 2006-03-01 CA CA2819464A patent/CA2819464A1/en not_active Abandoned
- 2006-03-01 EP EP11184538A patent/EP2436687A1/en not_active Withdrawn
- 2006-03-01 CN CN2006800149950A patent/CN101208352B/zh not_active Expired - Fee Related
- 2006-03-01 JP JP2007557300A patent/JP5154954B2/ja not_active Expired - Fee Related
- 2006-03-01 EP EP06705254A patent/EP1869060B1/en not_active Not-in-force
- 2006-03-01 US US11/817,465 patent/US20080287375A1/en not_active Abandoned
- 2006-03-01 WO PCT/CA2006/000300 patent/WO2006092049A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531604A5 (enExample) | ||
| JP7189983B2 (ja) | 異常炎症反応に関連する状態を処置するための方法および組成物 | |
| CN117597327A (zh) | 药物制剂 | |
| JP2009536191A5 (enExample) | ||
| US20110224196A1 (en) | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent | |
| JP2009102342A5 (enExample) | ||
| KR20210154261A (ko) | 고용체 조성물 | |
| JP2011057693A5 (enExample) | ||
| JP2007533625A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| ES2449340T3 (es) | Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2015535247A5 (enExample) | ||
| US20240139224A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2014510782A5 (enExample) | ||
| WO2009149166A3 (en) | Methods and compositions for the diagnosis and treatment of proliferative disorders | |
| JP2010505936A (ja) | 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ | |
| RU2006141276A (ru) | Производное пурина | |
| JP2008500378A5 (enExample) | ||
| WO2007054348A1 (de) | Neue arzneimittel | |
| ES2526398T3 (es) | Composiciones inhibidoras de la recaptación de serotonina-norepinefrina para tratar el dolor crónico | |
| JP2006514063A5 (enExample) | ||
| US9073884B2 (en) | Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them | |
| CA2684171C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| US20110144064A1 (en) | Inhibitors of Kynurenine Aminotransferase and Uses Therefor |